A COVID-19 vaccine based on mRNA technology has changed the landscape of the human battle against the SARS-CoV-2 virus. Comirnaty (BNT162b2), developed by pharma giant
On November 8, GlaxoSmithKline (GSK) announced that the phase IIb clinical results of the antisense oligonucleotide bepirovirsen in the treatment of chronic hepatitis B will
The excellent efficacy of targeted drugs and the inevitable problem of drug resistance have been in a state of ebb and flow. Researchers continue to
Antibodies of ADC drugs are antibodies targeting tumor cell antigens, which are linked to small-molecule drug poisons through linkers to kill tumor cells and surrounding
On November 7, GSK announced that the Phase III open-label, randomized, head-to-head superiority DREAMM-3 trial failed to meet the primary endpoint of progression-free survival (PFS).
On November 3, Affimed announced that it will present an update on the ongoing Phase I/II clinical trial at the ASH Congress. The study was
AB-836, a next-generation oral hepatitis B virus (HBV) capsid inhibitor (class II capsid inhibitor) that Arbutus Biopharma is developing for the treatment of chronic hepatitis
In July of this year, DeepMind, which developed AlphaFold, announced that it had increased the amount of predicted protein structure data from 1 million to
Antibody-drug conjugate (ADC) therapy has developed rapidly in recent decades. Currently, 14 products have been approved worldwide and more than 140 ADCs are in clinical
On November 4, German Chancellor Schultz announced a new agreement with the Chinese government. The Chinese government approved Germany’s BioNTech’s covid-19 vaccine for use by
On November 3, the Institute of Clinical and Economic Review (ICER) announced that, after a cost-benefit analysis, it assessed the price ceiling of Roctavian (valoctocogene
Foreword The mucin (MUC) family is a group of highly glycosylated macromolecules that are abundantly expressed in mammalian epithelial cells. Mucins contribute to the formation
